多発性嚢胞腎‐ここ１０年の進展と２００２年の話題‐

• 香村 衡一

  国立佐倉病院泌尿器科

書誌事項

タイトル別名

• POLYCYSTIC KIDNEY DISEASE: CLINICAL ADVANCES IN THE PAST 10 YEARS AND TOPICS IN 2002
• ―ここ10年の進展と2002年の話題―

抄録

The year 2002 was an epoch-making year for the pathogenesis and treatment of polycystic kidney disease (PKD). The last genetic puzzle concerning major PKD gene, the gene PKHD1 causing autosomal recessive PKD had remained elusive for many years. However, cloning of the gene PKHD1 was achieved at the beginning of the year. In the end of the year, it was elucidated that most of the different kinds of PKD gene products concentrated in the cilia of the renal tubular epithelial cells. In the field of therapy, an angiotensin II receptor blocker, candesartan, was reported to better preserve renal function of autosomal dominant PKD patients with hypertension than calcium antagonist did. On the other hand, the candidate medicine for PKD, pioglitazone, which was already being used as a drug for diabetes mellitus was proposed as an effective drug. For the mass effect of PKD and polycystic liver disease transcatheter renal and hepatic arterial embolization treatment was established.<br>In this review, the author explains clinical development against PKD in the past 10 years in Japan as well as major topics of PKD in 2002.

収録刊行物

• 医療

  医療 57 (9), 551-557, 2003

  一般社団法人 国立医療学会

キーワード

• 多発性嚢胞腎
• 進歩
• 話題

詳細情報

• CRID: 1390001206313968640
• NII論文ID: 130004316209
• DOI: 10.11261/iryo1946.57.551
• ISSN: 18848729
• ISSN: 00211699
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可